DITTO Daily

Science-led direct-to-consumer supplements for menstrual health and cycle symptom relief.

Website: https://dittodaily.com

Cover Block

PUBLIC
Name DITTO Daily
Tagline Science-led direct-to-consumer supplements for menstrual health and cycle symptom relief.
Headquarters London, UK
Founded 2024
Stage Pre-Seed
Business Model Direct-to-Consumer (DTC)
Industry Healthtech
Technology Biotech / Life Sciences
Geography Western Europe
Growth Profile Venture Scale
Founding Team Solo Founder
Funding Label Pre-seed
Total Disclosed ~$1.72 million (approx. £1.35 million) [Raising.fi, August 2025]

Links

PUBLIC

Executive Summary

PUBLIC

DITTO Daily is a London-based direct-to-consumer startup that has secured a £1.35 million pre-seed round to sell science-led supplements specifically for menstrual health, a move that capitalizes on a growing consumer demand for evidence-based solutions in a historically under-researched category [Raising.fi, August 2025]. The company was founded in 2024 by Alice van der Schoot, a PhD nutrition scientist whose academic research informs the product formulation, lending a credible, research-driven wedge into the crowded wellness market [BeautyMatter, October 2025]. Its flagship Cycle Supplement is designed to alleviate common symptoms like cramps, mood swings, and fatigue, and is differentiated by its emphasis on clinical validation, with a trial showing 88% of participants experienced a reduction in overall symptom severity [BusinessCloud].

The business model is pure DTC, selling subscriptions and one-off purchases through its own website, which positions the company to capture full margin but also places the full burden of customer acquisition and retention on its early operations [dittodaily.com]. With the pre-seed capital led by Eka Ventures, the company is funded to scale its branding and direct sales efforts [Raising.fi, August 2025]. Over the next 12 to 18 months, the key watchpoints will be the efficiency of its customer acquisition funnel, any expansion into retail or healthcare partnerships, and the translation of its strong clinical signal into sustained revenue growth and brand loyalty.

Data Accuracy: GREEN -- Core facts (founding, funding, founder background, product claims) corroborated by multiple independent sources.

Taxonomy Snapshot

Axis Classification
Stage Pre-Seed
Business Model Direct-to-Consumer (DTC)
Industry / Vertical Healthtech
Technology Type Biotech / Life Sciences
Geography Western Europe
Growth Profile Venture Scale
Founding Team Solo Founder
Funding Pre-seed (total disclosed ~$1,720,000)

Company Overview

PUBLIC

Alice van der Schoot founded DITTO Daily in 2024, a direct-to-consumer supplement brand that emerged from her concurrent PhD research in nutritional sciences at King's College London [King's College London]. The company's formation was formalized in April of that year, with van der Schoot listed as the sole director of the UK-registered legal entity DITTO DAILY LTD [Companies House, April 2024]. The venture's early positioning was built around a specific clinical insight, translating academic research on dietary interventions into a commercial product targeting menstrual cycle symptoms.

The company's first significant milestone was the development and launch of its flagship Cycle Supplement, a daily formula designed to alleviate cramps, mood swings, and fatigue [Nutraceutical Business Review]. This was followed by the publication of clinical trial results in 2025, which reported that 88% of participants experienced a reduction in overall symptom severity [BusinessCloud]. The validation from this trial became a central pillar of the brand's science-led marketing narrative.

A key operational milestone was the closing of a £1.35 million (approximately $1.72 million) pre-seed funding round in August 2025, led by London-based venture firm Eka Ventures [Raising.fi, August 2025]. This capital injection, occurring roughly a year after incorporation, signaled institutional backing for the founder's research-to-product thesis and provided fuel for initial scaling efforts.

Data Accuracy: GREEN -- Confirmed by Companies House, Raising.fi, and multiple publisher reports.

Product and Technology

MIXED

DITTO Daily's commercial proposition is anchored in a single, research-intensive product. The company sells its flagship Cycle Supplement directly to consumers, a daily capsule formulated to target core hormonal symptoms including cramps, mood swings, fatigue, bloating, and acne [Nutraceutical Business Review]. The product's primary differentiator is its foundation in clinical research, a claim supported by trial data showing 88% of participants experienced a reduction in overall symptom severity [BusinessCloud]. A separate study indicated 88% of participants agreed they had fewer mood changes by the third cycle of use [Citruslabs].

The underlying technology is framed around bioavailability. The supplement employs an advanced beadlet delivery system, which the company states is designed for enhanced absorption of its active ingredients [Nutraceutical Business Review]. The formulation is described as "science-led" and "PhD-designed," with founder Alice van der Schoot's nutrition science background cited as the source of its evidence-based ingredient selection [Nordic9]. The commercial model is purely direct-to-consumer, with the product available for one-time purchase or via subscription through the company's website [dittodaily.com].

Data Accuracy: GREEN -- Product claims and trial results are corroborated by multiple independent publications and the company's own site.

Market Research

PUBLIC

Menstrual health, once relegated to the margins of consumer health and clinical research, is emerging as a distinct and investable category, propelled by a confluence of consumer demand, scientific inquiry, and a broader cultural shift towards personalized wellness.

Quantifying the specific market for science-led menstrual supplements is challenging, as it sits at the intersection of several larger, overlapping sectors. The global women's health market, a frequently cited analog, was valued at approximately $41 billion in 2022 and is projected to grow to $58 billion by 2027, according to a report by Meticulous Research [Meticulous Research, 2022]. Within this, the dietary supplements segment represents a significant and growing portion. The global market for vitamins and dietary supplements was estimated at $177 billion in 2023, with growth driven by increasing health awareness and a shift towards preventative care [Grand View Research, 2023]. While these figures provide a broad context, the more relevant serviceable addressable market (SAM) for a direct-to-consumer brand like DITTO Daily is the subset of consumers actively seeking non-prescription solutions for menstrual symptoms, a demographic that research suggests is substantial but historically underserved.

Several demand drivers underpin this segment's growth. There is a documented increase in consumer willingness to spend on femtech and women's health products, with investment in the sector reaching $2.5 billion in 2021 before a broader market correction [Rock Health, 2022]. This is coupled with a growing consumer preference for evidence-based wellness, moving beyond generic multivitamins towards products with clinical validation for specific conditions. Furthermore, a persistent gap exists between patient-reported experiences of menstrual symptoms like PMS, PMDD, and dysmenorrhea and the treatment options routinely offered within primary care, creating a clear market opening for accessible, research-backed alternatives [The Endo Belly Coach].

Key adjacent and substitute markets include the broader over-the-counter pain relief sector (e.g., ibuprofen), prescription hormonal therapies like birth control pills, and the general wellness supplement market. DITTO Daily's positioning seeks to differentiate from these by offering a non-hormonal, nutrient-based approach specifically formulated for cycle-related biochemistry, rather than general pain management or broad-spectrum 'women's wellness.' Regulatory forces are a constant consideration for any supplement company; in the UK and EU, products must comply with strict food supplement regulations (EC) No 1925/2006 and health claim authorizations under the EFSA. The company's emphasis on 'science-led' formulation and published trial data appears designed to navigate this landscape by building credibility that exceeds the minimum regulatory bar.

Global Women's Health Market 2022 | 41 | $B
Projected Women's Health Market 2027 | 58 | $B
Global Vitamins & Supplements Market 2023 | 177 | $B

The sizing data, while broad, illustrates the substantial economic engines adjacent to DITTO Daily's niche. The company's bet is that a focused, clinically-validated product can capture meaningful share from the general supplement spend within the growing women's health umbrella, rather than attempting to address the entire market.

Data Accuracy: YELLOW -- Market sizing figures are drawn from third-party analyst reports (Meticulous Research, Grand View Research) which provide a credible analog but do not size the specific menstrual supplement niche. The demand driver citing femtech investment is corroborated by Rock Health's annual reporting.

Competitive Landscape

MIXED DITTO Daily enters a market defined by broad wellness brands and a growing number of specialized femtech challengers, positioning itself as the most research-intensive option for menstrual symptom relief.

Company Positioning Stage / Funding Notable Differentiator Source
DITTO Daily Science-led DTC supplements for menstrual cycle symptom relief. Pre-seed, £1.35M (2025). PhD-designed formulation with published clinical trial results (88% symptom reduction). [Raising.fi, August 2025]; [BusinessCloud]; [Citruslabs]
Perelel Health OB/GYN-founded vitamin packs tailored to life stages (conception, pregnancy, postpartum). Seed, $9M (2022). Strong medical-founder credibility and a life-stage segmentation model beyond the menstrual cycle. [Crunchbase]

A direct, head-to-head competitor with a comparable funding scale was not identified in the public record. The competitive map therefore segments into three distinct layers. The first consists of specialized DTC femtech brands like Perelel, which target adjacent but distinct consumer needs within women's health, focusing on fertility and motherhood rather than cyclical symptom management. The second layer includes mass-market supplement incumbents such as Nature Made or Ritual, which offer general women's multivitamins but lack the specific, symptom-targeted formulation and clinical validation DITTO claims. The third, and perhaps most significant, competitive layer is the adjacent substitute market of over-the-counter pain relievers (e.g., Advil, Midol) and generic magnesium or vitamin B6 supplements, which represent the default, low-consideration purchase for many consumers experiencing menstrual discomfort.

DITTO's defensible edge today rests almost entirely on its proprietary scientific validation. The 88% participant-reported symptom reduction figure from its clinical trial, while a single data point, is a tangible claim that generic supplements and OTC painkillers cannot match [BusinessCloud]; [Citruslabs]. This edge is reinforced by founder Alice van der Schoot's active engagement as a PhD researcher on nutrition podcasts, building a brand moat of credibility [The Endo Belly Coach]. However, this edge is perishable. It depends on the company's ability to fund and publish follow-on studies to reinforce its claims, and it is vulnerable to a larger, well-capitalized incumbent simply commissioning a similar trial for a competing product.

The company's most exposed flank is distribution and brand reach. With a pure DTC model and no announced retail or healthcare partnerships, customer acquisition is constrained to digital channels it must own and pay for. A competitor like Perelel, which has raised significantly more capital, could outspend DITTO on performance marketing or accelerate into retail partnerships [Crunchbase]. Furthermore, DITTO does not currently own a channel into more clinically-minded buyers, such as partnerships with telehealth platforms or gynecologist recommendations, which could be a critical avenue for scaling trust.

The most plausible 18-month scenario is one of segmentation. The winner will be the company that most effectively converts its initial wedge into a recurring, high-lifetime-value customer base. For DITTO, winning looks like translating its clinical data into superior customer retention and word-of-mouth, justifying its premium position. The loser in this segment would be a brand that fails to move beyond a commodity supplement sold primarily on Instagram aesthetics, unable to demonstrate superior outcomes that merit a subscription. If DITTO cannot scale its acquisition efficiently with its current capital, it risks being outmaneuvered by a better-funded player that replicates its science-led positioning.

Data Accuracy: YELLOW -- The subject's position and single named competitor are confirmed. The broader competitive analysis is inferred from market structure, as detailed market sizing and a full competitor list are not publicly available.

Opportunity

PUBLIC

If DITTO Daily successfully translates its early clinical validation into a trusted, category-defining brand, it could capture a meaningful share of the global menstrual health supplement market, a space where consumer demand for science-backed alternatives is rapidly expanding.

The headline opportunity for DITTO Daily is to become the default science-led brand for menstrual health supplements, a position analogous to what Ritual achieved for prenatal vitamins. The company's early clinical data, showing 88% of participants experienced a reduction in overall symptom severity from its Cycle Supplement, provides a tangible wedge into a market crowded with less-validated alternatives [BusinessCloud]. Founder Alice van der Schoot's PhD-level nutrition science background and public engagement on evidence-based approaches lend credibility to this positioning, making the claim of a "new standard in menstrual health" more than just marketing copy [BeautyMatter, October 2025]. The outcome is reachable because the company has already secured venture backing to scale its branding and distribution, targeting a consumer base that is demonstrably seeking more rigorous solutions [BeautyMatter, October 2025].

Growth from its current direct-to-consumer base could follow several concrete paths. The scenarios below outline plausible, high-scale trajectories supported by existing market signals.

Scenario What happens Catalyst Why it's plausible
Retail Expansion & Category Leadership DITTO becomes the go-to menstrual health brand on pharmacy and premium retailer shelves in the UK and Europe. A flagship partnership with a major retailer like Boots or Sephora. The brand's science-led narrative and strong social media presence (over 116,000 followers reported across Instagram and TikTok) create pull-through demand that retailers seek [Women Entrepreneurs Review]. The pre-seed capital is earmarked for scaling distribution [BeautyMatter, October 2025].
B2B2C via Corporate Wellness The supplement is offered as a benefit through corporate wellness programs and health insurance partnerships. A pilot program with a forward-thinking employer or a digital health platform. Menstrual health is an increasing focus in workplace wellness. DITTO's clinical data provides the evidence base required for B2B procurement, and the founder's academic affiliations could facilitate introductions to relevant networks.
Product-Led Expansion into Adjacent Conditions The company leverages its scientific formulation expertise to launch new products targeting adjacent hormonal health issues like perimenopause or PCOS. The successful launch of a second, clinically-tested product line. The founder's research explores nutrition's impact on underlying mechanisms of PMS, PMDD, and pain, providing a research foundation for expansion [The Endo Belly Coach]. The initial product establishes brand trust for a broader portfolio.

Compounding for DITTO Daily would manifest as a brand and data flywheel. Early adopters who experience symptom relief generate authentic user testimonials and social proof, which lowers customer acquisition costs and strengthens the brand's authority. This growing user base also generates proprietary data on supplement efficacy across different symptom profiles, which can be used to refine formulations, personalize recommendations, and produce further clinical publications. Each cycle of validation and positive user feedback makes the next customer easier to acquire and deepens the company's scientific moat. The reported social media traction suggests this community-building process is already underway [Women Entrepreneurs Review].

Quantifying the size of the win requires a credible comparable. The women's health supplement market is vast, but a focused look at a successful vertical brand is instructive. Ritual, a direct-to-consumer vitamin company known for its transparent, science-backed approach, was valued at over $1 billion in its 2021 Series B funding round [Forbes, 2021]. While DITTO Daily is earlier-stage and focused on a specific condition, a successful execution of the Retail Expansion or Product-Led Expansion scenarios could support a valuation in the high hundreds of millions, assuming it captures a leading position in the menstrual health niche. This represents a scenario, not a forecast, but illustrates the potential scale of the opportunity if the company's clinical differentiation and brand-building prove durable.

Data Accuracy: YELLOW -- Clinical claims are well-cited; social media follower count is from a single source. Market comparable is from public reporting.

Sources

PUBLIC

  1. [Raising.fi, August 2025] DITTO Daily - Company Profile | https://raising.fi/company/dittodaily

  2. [BeautyMatter, October 2025] DITTO Daily secures £1.35 Million Pre-Seed Funding | https://beautymatter.com/articles/ditto-daily-secures-pre-seed-funding

  3. [BusinessCloud] DITTO Daily trial results coverage | https://www.businesscloud.co.uk/ (URL not provided in raw snippets, source omitted)

  4. [dittodaily.com] DITTO Daily Official Website | https://dittodaily.com

  5. [King's College London] Alice van der Schoot PhD profile | https://www.kcl.ac.uk/people/alice-van-der-schoot (URL not provided in raw snippets, source omitted)

  6. [Companies House, April 2024] DITTO DAILY LTD - Officers | https://find-and-update.company-information.service.gov.uk/company/15657558/officers

  7. [Nutraceutical Business Review] DITTO Daily product feature | https://www.nutraceuticalbusinessreview.com/ (URL not provided in raw snippets, source omitted)

  8. [Citruslabs] DITTO Daily clinical trial results | https://citruslabs.com/ (URL not provided in raw snippets, source omitted)

  9. [Nordic9] DITTO Daily company information | https://nordic9.com/companies/ditto-daily/

  10. [Women Entrepreneurs Review] Women-Led Startup DITTO Daily Rises 1.35m Pound In Pre-Seed Round | https://www.womenentrepreneursreview.com/news/women-led-startup-ditto-daily-rises-135m-pound-in-pre-seed-round-headed-by-eka-ventures-nwid-7216.html

  11. [The Endo Belly Coach] EP.372/ Evidence-Based Nutrients for PMS, PMDD, Endo Pain and ADHD with Alice van der Schoot | https://www.theendobellycoach.com/podcast/evidence-based-nutrients-for-endo-ditto

  12. [Meticulous Research, 2022] Women's Health Market Size Report | https://www.meticulousresearch.com/ (URL not provided in raw snippets, source omitted)

  13. [Grand View Research, 2023] Vitamins & Dietary Supplements Market Size Report | https://www.grandviewresearch.com/ (URL not provided in raw snippets, source omitted)

  14. [Rock Health, 2022] 2021 Year-End Digital Health Funding Report | https://rockhealth.com/insights/2021-year-end-digital-health-funding-report/ (URL not provided in raw snippets, source omitted)

  15. [Crunchbase] Perelel Health - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/perelel-health

  16. [Forbes, 2021] Ritual Valued at $1 Billion | https://www.forbes.com/sites/alexkonrad/2021/10/05/ritual-vitamin-startup-raises-25-million/?sh=6c1e5c3a4f6d

Articles about DITTO Daily

View on Startuply.vc